ArticleAnnals of Indian Academy of Neurology2025
Sarcopenia and its Cognitive Consequences: Insights from an Urban Indian Cohort.
Article in Annals of Indian Academy of Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correspondence: Sarcopenia and its Cognitive Consequences: Insights from an Urban Indian Cohort.Annals of Indian Academy of Neurology · 2026Article
- Authors' reply- Sarcopenia and its Cognitive Consequences: Insights from an Urban Indian Cohort.Annals of Indian Academy of Neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesSarcopenia is associated with an increased risk of cognitive impairment. The current study aims to explore the cognitive profiles of individuals with sarcopenia in an urban Indian cohort.
methodsCognitively healthy participants (N = 1119) aged ≥45 years from the Tata Longitudinal Study of Aging were considered for the study. Sarcopenia was screened using two parameters: calf circumference (M < 34 cm, F < 33 cm) and handgrip strength (M < 28 kg, F < 18 kg). Based on these, participants were classified into three groups, namely healthy (satisfying neither criterion), intermediate (satisfying one criterion), and sarcopenia (satisfying both criteria). Detailed clinical assessments were done. Cognitive functioning was assessed using the Hindi Mental State Examination and Addenbrooke's Cognitive Examination-III (ACE-III).
resultsThe mean age of the participants was 62.03 ± 9.33 years. Of these, 405 (36.2%) participants were healthy controls, 502 (44.9%) were in the intermediate group, and 212 (18.9%) participants belonged to the sarcopenia group. Sarcopenia was significantly associated with diabetes. A generalized linear model, adjusted for sociodemographic features and comorbidities, revealed that the intermediate group had lower scores in the ACE-III fluency test ( P = 0.025), while the sarcopenia group had lower scores in the ACE-III total ( P = 0.002), ACE-III attention ( P = 0.031), and ACE-III fluency ( P < 0.001) tests when compared to the healthy group.
conclusionsOur study found an important link between sarcopenia and impaired cognitive performance, particularly in attention and verbal fluency. These findings highlight the importance of early detection and interventions targeting physical activity and nutrition, with an effort to mitigate or prevent age-related muscle loss and cognitive impairment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.